Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
- Status
- RECRUITING
- Phase
- PHASE2
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Agnostic Therapy in Rare Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- Status
- RECRUITING
- Phase
- PHASE2
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- Status
- RECRUITING
- Phase
- PHASE2
CD8 PET Imaging in Metastatic Solid Tumours
- Status
- RECRUITING
- Phase
- PHASE2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
- Status
- RECRUITING
- Phase
- NA